Bacci G, Picci P, Mercuri M, Ferrari S, Longhi A, Cesari M, Rosito P, Mancini A F, Barbieri E, Baldini N
Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy.
Acta Oncol. 1998;37(7-8):671-6. doi: 10.1080/028418698430025.
Clinicopathologic variables associated with a good histological response to primary chemotherapy in Ewing's sarcoma are identified. The histological response to preoperative chemotherapy in 243 cases of Ewing's sarcoma treated with neoadjuvant chemotherapy was analyzed in relation to different clinicopathological features (sex and age of the patients, tumor size, serum lactate dehydrogenase (LDH) levels, tumor site) and to the type and schedule of anticancer drugs delivered preoperatively according to three consecutive chemotherapy regimens. A higher rate of good responses was achieved with the use of ifosfamide and dactinomycin in addition to a conventional three-drug VAC regimen, suggesting that these drugs should be included from the beginning in neoadjuvant regimens for the treatment of Ewing's sarcoma. The analysis of event-free survival in 158 patients with a 4-year minimum follow-up confirmed that histological response to preoperative chemotherapy is a reliable predictor of outcome in Ewing's sarcoma.
确定了与尤因肉瘤对原发性化疗具有良好组织学反应相关的临床病理变量。分析了243例接受新辅助化疗的尤因肉瘤患者术前化疗的组织学反应与不同临床病理特征（患者的性别和年龄、肿瘤大小、血清乳酸脱氢酶（LDH）水平、肿瘤部位）以及根据三种连续化疗方案术前给予的抗癌药物类型和疗程的关系。除了传统的三联药物VAC方案外，使用异环磷酰胺和放线菌素可获得更高的良好反应率，这表明这些药物应从一开始就纳入尤因肉瘤治疗的新辅助方案中。对158例至少随访4年的患者的无事件生存期分析证实，术前化疗的组织学反应是尤因肉瘤预后的可靠预测指标。
